Loading market dashboard
Merck & Co., Inc.
MRKHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth rate has been better than that of many dividend-focused funds.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
Merck & Co., Inc. has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite looming patent expiry in 2028. MRK has aggressively pursued acquisitions and partnerships, notably with Terns Pharma, Cidara, Verona, and Daiichi Sankyo, to diversify its pipeline. By 2030, I project MRK can offset Keytruda declines with ~$17.35bn in new product revenues, supporting a potential $350bn valuation—~15% above current levels.
Explore how sector weightings and stock selection shape risk and return for these two leading dividend ETFs, each with distinct strategies and top holdings.
From a technical perspective, Merck (MRK) is looking like an interesting pick, as it just reached a key level of support. MRK recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Merck (MRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRK broke out above the 50-day moving average, suggesting a short-term bullish trend.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Explore the exciting world of Merck (MRK +4.79%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification Transcript
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available as an Ebola treatment to address the widening outbreak in the Democratic Republic of Congo, a senior executive told Reuters.
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone Intismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345]) CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage III/IV) following complete resection. These data will be presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2) and published simultaneously in ASCO's Journal of Clinical Oncology.
Biotech companies have always licensed programs, but never so many from one region in particular.
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and e.
When choosing dividend ETFs, diversification is a top priority.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference.
Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster — but VP of Digital Platforms Sean Finnerty says the only reason it's working is because they built the infrastructure first. And the pharmaceutical manufacturer is seeing promising early results: AI is generating marketing drafts that are “99% right” when it comes to compliance, shrinking review cycles from months to days and accelerating delivery by 70% to 80%.
Merck said its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the world's largest chicken-rearing country, which is home to over 5 billion birds.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2026 Dividend.
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend the dominance of blockbuster cancer drug Keytruda ahead of looming patent expirations later this decade. The rally followed encouraging Phase 3 clinical trial results involving sacituzumab tirumotecan, or sac-TMT, an antibody-drug conjugate developed in partnership with Sichuan Kelun-Biotech Biopharmaceutical.
Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the "go ahead" from European officials in regard to its combination of the company's products, Keytruda and Padcev, for a lower risk form of bladder cancer treatment.
Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for ad.
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the main goal of a late-stage study.
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Thursday.
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs. A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs.
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Merck said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer.
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company's comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinforce the long-term impact of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and Merck's rapidly advancing pipelin.
UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.
Merck (MRK) is moving toward a potentially high-stakes courtroom test over Gardasil, its HPV vaccine, as personal injury lawyers try to convince a Los Angeles j
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company's investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science. “Macrocyclic peptides have the potential to unlock new opportunities to develop oral treatment options for challenging therapeutic targets and broaden p.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels. Leveraging Agentfo.
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday that benefited from lower oil prices, some strong earnings, and solid buying from retail investors. At the same time, hedge funds continue to... Here Are Wednesday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report.
